+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetic Retinopathy - Global Strategic Business Report

  • ID: 1244804
  • Report
  • Region: Global, United States
  • 325 Pages
  • Global Industry Analysts, Inc
1 of 3
This report analyzes the US Market for Diabetic Retinopathy in US$ Million. Annual estimates and forecasts are provided for the period 2011 through 2015. The report profiles 40 companies including many key and niche players such as Allergan, Inc., AstraZeneca PLC., Eyetech, Inc., Fovea Pharmaceuticals SA, Genentech, Inc., Gene Signal, Isis Pharmaceuticals, Inc., Lpath, Inc., MacuSight, Inc., OM Pharma S.A, OPKO Health, Inc., Oxford BioMedica Plc., pSivida Corp., Quark Pharmaceuticals, Inc., Sanwa Kagaku Kenkyusho Co., Ltd., Sirnaomics, Inc., Suzuken Co., Ltd., and Vitreoretinal Technologies, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying
Note: Product cover images may vary from those shown
2 of 3
DIABETIC RETINOPATHY

A US MARKET REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3

II. A US MARKET REPORT

1. MARKET OUTLOOK II-1
Incidence and Prevalence of Diabetic Retinopathy Continue to Rise II-1
Table 1: Diabetic Retinopathy Patient Prevalence in the US by
Diabetes Type: 2006-2015 (In Thousand Patients) (includes
corresponding Graph/Chart) II-2

Table 2: Diabetic Retinopathy Patient Prevalence in the US by
Age Group: 2006-2012 (includes corresponding Graph/Chart) II-2

Table 3: Diabetic Retinopathy Prevalence in Type-1 Diabetic
Patients in the US by Age Group: 2006-2012 (includes
corresponding Graph/Chart) II-3
Prevalence of Diabetes on the Rise II-3
Huge Unmet Needs Fuel Demand for Pharmacological Drugs II-3
Market Awaits First Approved Drug
Off-label Use Continues II-4
Diabetic Retinopathy Drug Market to Post Dramatic Growth II-4
Insulin - A Potential Therapy for Diabetic Retinopathy II-4
Additional Trials Delay Arxxant's Launch II-5
Lucentis Shows Promise in Diabetic Retinopathy Treatment II-5
Avastin and Lucentis to Compete on Price II-6
Pycnogenol Continues to Appeal to Researchers II-6
Robo4 Protein - A Potential Therapeutic for Diabetic Retinopathy II-7
Bevacizumab Bodes Potential As An Adjunct to Surgery PDR
Treatment II-7

2. DIABETIC RETINOPATHY DRUG CLASS - AN OVERVIEW II-8

DRUG CLASSES IN DIABETIC RETINOPATHY II-8
VEGF Inhibitors II-8
Pegaptanib II-8
Bevacizumab II-8
Ranibizumab II-8
PKC Inhibitors II-9
Corticosteroids II-9
Aldose Reductase - AGE Inhibitors II-10
Somatostatin Analog II-11
Other Pharmacological Therapeutic Agents II-11

3. PIPELINE OVERVIEW II-12
Select Pipeline Drugs in Diabetic Retinopathy Market II-12
An Overview of Select Pipeline Drugs II-13
Arxxant (Eli Lilly) II-13
Iluvien® (pSivida Corp.) II-13
Atacand (AstraZeneca) II-13
Lucentis (Genentech and Novartis) II-14
Avastin (Genentech/Roche) II-14
Vitreosolve® (Vitreo Retinal Technologies) II-14
Posurdex (Allergan) II-15
Macugen (EyeTech) II-15
Cand5 (Opko Health, Inc.) II-15
PF-4523655 (Quark Pharmaceuticals/Pfizer) II-16
Intravitreal Triamcinolone Acetonide (Allergan) II-16
Peribulbar Triamcinolone Acetonide (Bristol Myers) II-16
Microplasmin (ThromboGenics N.V.) II-17
Aflibercept (Regeneron/Bayer) II-17
Sirolimus (MacuSight/Santen) II-18
iCo-007 (iCo Therapeutics) II-18
Other Drugs with Potential Benefits in DR Treatment II-19

4. DISEASE OVERVIEW II-20
Diabetes II-20
Quick Facts on Diabetes II-20
Diabetic Retinopathy II-20
Leading Cause of Blindness in Diabetic Population II-21
Pathogenesis of Diabetic Retinopathy II-21
Clinical Features II-22
Proliferative and Non-Proliferative Diabetic Retinopathy II-22
Diabetic Macular Edema II-23
Risk Factors for the Condition II-23
Symptoms II-25
Prevention of Diabetic Retinopathy II-26
Detection of Proliferative Retinopathy and Macular Edema II-26
Visual Acuity Test II-26
Fundus Fluorescein Angiography II-27
Ophthalmoscopy II-27
Optical Coherence Tomography II-27
Non-Mydriatic Fundus Photography II-27
Dynamics of Evaluating Technologies II-28
Frequency of Examinations II-28
Treatment for Diabetic Retinopathy II-29
Laser Surgery II-29
Scatter Laser Treatment/ Panretinal Photocoagulation II-29
Focal Laser Treatment/ Photocoagulation II-30
Vitrectomy II-30
Kenalog/ Triamcinolone Actinomide II-31

5. RECENT INDUSTRY ACTIVITY II-32
Sanofi-Aventis to Take Over Fovea Pharmaceuticals II-32
New Injectable Steroid In-Line from Wakamoto Pharmaceutical II-32
Sirion Therapeutics and Advanced Vision Research Signs Agreement II-33
ActiveSite Develops Protease Inhibitor for Treating Diabetic
Retinopathy II-33
Pipex Acquires Global License for Additional Usage of Oral
Flupirtine II-34
MacuSight and Santen Ink License Agreement II-34
OptiMedica Enters into Distribution Agreement with Topcon Medical II-35
Lpath Submits IND for iSONEP™ II-35
Iris Pharma Merges with Clirophtha II-36
Isis Receives Milestone Payment for Initiating Trials of iCo-007 II-36
Eli Lilly Withdraws Marketing Authorization Application for
Arxxant in Europe II-37
ThromboGenics Begins Phase IIb Trial of Microplasmin in the US II-37

6. FOCUS ON SELECT GLOBAL PARTICIPANTS II-38
Allergan, Inc. (US) II-38
AstraZeneca PLC (UK) II-38
Eyetech, Inc. (US) II-38
Fovea Pharmaceuticals SA (France) II-39
Genentech, Inc. (US) II-39
Gene Signal (Switzerland) II-39
Isis Pharmaceuticals, Inc. (US) II-40
Lpath, Inc. (US) II-40
MacuSight, Inc. (US) II-41
OM PHARMA S.A (Switzerland) II-41
OPKO Health, Inc. (US) II-42
Oxford BioMedica Plc. (UK) II-42
pSivida Corp. (US) II-42
Quark Pharmaceuticals, Inc. (US) II-43
Sanwa Kagaku Kenkyusho Co., Ltd. (Japan) II-43
Sirnaomics, Inc. (US) II-44
Suzuken Co., Ltd. (Japan) II-44
Vitreoretinal Technologies, Inc. (US) II-44

7. US MARKET FORECASTS II-45
Table 4: US Diabetic Retinopathy Drugs Market Potential:
Annual Sales Forecasts in US$ Million for Years 2011 through
2015 (includes corresponding Graph/Chart) II-45

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 40 (including Divisions/Subsidiaries - 43)
  • --------
Region/Country Players
  • --------
The United States 25
Canada 1
Japan 5
Europe 12
France 4
Germany 1
The United Kingdom 2
Rest of Europe 5
  • --------
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/1244804
Adroll
adroll